A randomized controlled trial of rebamipide plus rabeprazole for the healing of artificial ulcers after endoscopic submucosal dissection

Journal of Gastroenterology

Volumn 46, Issue 5, 2011, Pages 595-602

  Fujiwara, Shoko ^a   Morita, Yoshinori ^a   Toyonaga, Takashi ^a   Kawakami, Fumi ^a   Itoh, Tomoo ^a   Yoshida, Masaru ^a   Kutsumi, Hiromu ^a   Azuma, Takeshi ^a  

^a KOBE UNIVERSITY   (Japan)

Author keywords

Artificial ulcer; Atrophic gastritis; ESD; PPI; Rebamipide

Indexed keywords

OMEPRAZOLE; RABEPRAZOLE; REBAMIPIDE;

ABNORMAL FECES COMPOSITION; AGED; ARTICLE; ARTIFICIAL ULCER; ATROPHIC GASTRITIS; BLEEDING; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; ENDOSCOPIC SUBMUCOSAL DISSECTION; ESOPHAGOGASTRODUODENOSCOPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCAR STAGE; TARRY FECES; TREATMENT DURATION; ULCER; ULCER HEALING; UNSPECIFIED SIDE EFFECT;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; AGED; ALANINE; ANTI-ULCER AGENTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRIC MUCOSA; GASTRITIS, ATROPHIC; GASTROSCOPY; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTON PUMP INHIBITORS; QUINOLONES; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS; STOMACH ULCER;

EID: 79958765912     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-011-0372-3     Document Type: Article

References (23)

1. Matsuzaka M, Fukuda S, Takahashi I, Shimaya S, Oyama T, Yaegaki M, et al. The decreasing burden of gastric cancer in Japan. Tohoku J Exp Med. 2007;212:207-19. (Pubitemid 47304987)
2. Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, et al. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219-25. (Pubitemid 32290729)
3. Kakushima N, Yahagi N, Fujishiro M, Iguchi M, Oka M, Kobayashi K, et al. The healing of gastric ulcers after endoscopic submucosal dissection. Dig Endosc. 2004;16:327-31. (Pubitemid 39421399)
4. Fujiwara S, Morita Y, Toyonaga T, Itoh T, Yoshida M, Kutsumi H. Rebamipide combined with PPI enhances the healing process of post-ESD ulcer; a randomized prospective study. Endoscopy 2009;S1460.
5. Tarpila S, Kekki M, Samloff IM, Sipponen P, Siurala M. Morphology and dynamics of the gastric mucosa in duodenal ulcer patients and their first-degree relatives. Hepatogastroenterology. 1983;30:198-201. (Pubitemid 14241036)
6. Siurala M. Gastritis, its fate and sequelae. Ann Clin Res. 1981;13:111-3. (Pubitemid 11065975)
7. Siurala M, Sipponen P, Kekki M. Chronic gastritis: dynamic and clinical aspects. Scand J Gastroenterol. 1985;109(Suppl):69-76. (Pubitemid 15032502)
8. Yamasaki K, Kanbe T, Chijiwa T, Ishiyama H, Morita S. Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the rat. Eur J Pharmacol. 1987;142:23-9. (Pubitemid 17159903)
9. Terano A, Arakawa T, Sugiyama T, Suzuki H, Joh T, Yoshikawa T, et al. Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in Japanese population: a randomized, double-blind, placebo-controlled trial. J Gastroenterol. 2007;42:690-3. (Pubitemid 47278695)
10. Tarnawski A. Molecular mechanism of ulcer healing. Drug News Perspect. 2000;13:158-68.
11. Risau W. Mechanisms of angiogenesis. Nature. 1997;386:761-4.
12. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653-60. (Pubitemid 36749213)
13. Ferrara N, Gerber H-P, LeCourter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-76. (Pubitemid 36749215)
14. Tarnawski A, Arakawa T, Kobayashi K. Rebamipide treatment activates epidermal growth factor and its receptor expression in normal and ulcerated gastric mucosa in rats: one mechanism for its ulcer healing action? Dig Dis Sci. 1998;43:90S-8S.
15. Tarnawski A, Chai J, Pai R, Chiou SK. Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action? Dig Dis Sci. 2004;49:202-9.
16. Lee SY, Kim JJ, Lee JH, Kim YH, Rhee PL, Paik SW, et al. Healing rate of EMR-induced ulcer in relation to the duration of treatment with omeprazole. Gastrointest Endosc. 2004;60:213-7. (Pubitemid 38980671)
17. Sakita T, Fukushima H. Endoscopic diagnosis. In: Yoshitoshi Y, editor. Ulcer of the stomach and duodenum. Tokyo: Nankodo; 1971. p. 198-208 (in Japanese).
18. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1969;3:87-97.
19. Kato T, Araki H, Onogi F, Ibuka T, Sugiyama A, Tomita E, et al. Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection - a randomized controlled study. J Gastroenterol. 2010;45:285-90.
20. Uedo N, Takeuchi Y, Yamada T, Ishihara R, Ogiyama H, Yamamoto S, et al. Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol. 2007;102:1610-6. (Pubitemid 47206669)
21. Kakushima N, Fujishiro M, Yahagi N, Kodashima S, Nakamura M, Omata M. Helicobacter pylori status and the extent of gastric atrophy do not affect ulcer healing after endoscopic submucosal dissection. J Gastroenterol Hepatol. 2006;21:1586-9. (Pubitemid 44266519)
22. Asakuma Y, Kudo M, Matsui S, Okada M, Kawasaki M, Umehara Y, et al. Comparison of ecabet sodium and proton pump inhibitor (PPI) combination therapy with PPI alone in the treatment of endoscopic submucosal dissection (ESD)-induced ulcers in early gastric cancer: prospective randomized study. Hepatogastroenterology. 2009;56:1270-3.
23. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20:153-67.